Drug Trial Radar · NCT00042068
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Nov 1, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Actual
Start
Jun 2002
Primary completion
Not stated
Study completion Jul 2003
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 24, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.
Conditions
- Arthritis, Rheumatoid
Interventions
MeloxicamDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response according to American College of Rheumatology 20% (ACR20) classificationTime frame: at 12 weeks
Locations
153 sites in 14 countries. Site status is shown where the registry gives one.
Suites 570 (research) & 600 (PI)
Huntsville, Alabama
Suite 200
Montgomery, Alabama
Suite 140
Anchorage, Alaska
#106
Glendale, Arizona
Suite 601
Phoenix, Arizona
Suite 201
Phoenix, Arizona
Boehringer Ingelheim Investigational Site
Los Angeles, California
Boehringer Ingelheim Investigational Site
Pasadena, California
Suite 100
Rancho Cucamonga, California
Boehringer Ingelheim Investigational Site
Rancho Mirage, California
Suite 208
San Diego, California
Suite 202
San Diego, California
Suite 301
San Leandro, California
Suite A
Santa Maria, California
Westlake Medical Research
Westlake Village, California
Suite 200
Colorado Springs, Colorado
Suites 205 & 206
Danbury, Connecticut
Suite 300
Washington D.C., District of Columbia
Boehringer Ingelheim Investigational Site
Delray Beach, Florida
Boehringer Ingelheim Investigational Site
Gainsville, Florida
Boehringer Ingelheim Investigational Site
Jacksonville, Florida
Boehringer Ingelheim Investigational Site
Largo, Florida
Suite 202
Miami, Florida
Boehringer Ingelheim Investigational Site
Ocala, Florida
Renstar Medical Research
Ocala, Florida
Boehringer Ingelheim Investigational Site
Orlando, Florida
Suite 2
Orlando, Florida
Suite 406
Safety Harbor, Florida
Boehringer Ingelheim Investigational Site
Sarasota, Florida
Boehringer Ingelheim Investigational Site
South Miami, Florida
Suite 101
St. Petersburg, Florida
Radiant Research
Stuart, Florida
Suite 203
Tampa, Florida
Boehringer Ingelheim Investigational Site
Zephyrhills, Florida
Boehringer Ingelheim Investigational Site
Coeur d'Alene, Idaho
Suite 202
Idaho Falls, Idaho
Boehringer Ingelheim Investigational Site
Lake Forest, Illinois
Boehringer Ingelheim Investigational Site
Rockford, Illinois
Boehringer Ingelheim Investigational Site
Springfield, Illinois
Boehringer Ingelheim Investigational Site
Indianapolis, Indiana
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.